A national strategy for the elimination of hepatitis B and C : phase two report /

Saved in:
Bibliographic Details
Imprint:Washington, DC : The National Academies Press, [2017]
©2017
Description:1 online resource (xvi, 280 pages) : illustrations (some color)
Language:English
Subject:
Format: E-Resource Book
URL for this record:http://pi.lib.uchicago.edu/1001/cat/bib/11349607
Hidden Bibliographic Details
Other authors / contributors:Buckley, Gillian J., editor.
Strom, Brian L., editor.
National Academies of Sciences, Engineering, and Medicine (U.S.). Committee on a National Strategy for the Elimination of Hepatitis B and C, author.
ISBN:9780309457309
0309457300
9780309457293
0309457297
Notes:Includes bibliographical references.
"This acticivy was supported by the American Association for the Study of Liver Diseases, the Infectious Disseases Society of America, the National Viral Hepatitis Roudtable, and the U.S. Department of Health and Huyman Services/Centers for Disease Control and Prevention (Contract No. 200-2011-38807, Task Order #44. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project"--Title page verso.
Online resource; title from resource home page (National Academies Press, viewed July 17, 2017).
Summary:"Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the second of two, builds off the conclusions of the first report and outlines a strategy for hepatitis reduction over time and specific actions to achieve them"--Publisher's description.
Other form:Print version: National strategy for the elimination of hepatitis B and C. Washington, D.C. : National Academies Press, [2017] 9780309457293